Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore.
Duke-NUS Medical School, Singapore.
Pediatr Pulmonol. 2020 Apr;55(4):1000-1006. doi: 10.1002/ppul.24674. Epub 2020 Feb 3.
This study delineates the disease trajectory of patients with pediatric acute respiratory distress syndrome (PARDS) defined by the Pediatric Acute Lung Injury Consensus Conference (PALICC) definition, and evaluates the impact of comorbidities on outcomes.
This prospective study over November 2017-October 2019 was conducted in a single-center multidisciplinary pediatric intensive care unit (PICU) and included patients <21years of age with PARDS. Clinical history of those requiring mechanical ventilation for <3 days was interrogated and cases in which the diagnosis of PARDS were unlikely, identified. The impact of chronic comorbidities on clinical outcomes, in particular, pulmonary disease and immunosuppression, were analyzed.
Eighty-five of 1272 PICU admissions (6.7%) met the criteria for PARDS and were included. Median age and oxygenation indexes were 2.8 (0.6, 8.3) years and 10.6 (7.6, 15.4), respectively. Overall mortality was 12 out of 85 (14.1%). Despite fulfilling criteria in 6/85 (7.1%), hypoxemia contributed by bronchospasm, mucus plugging, fluid overload, and atelectasis was quickly reversible and PARDS was unlikely in these patients. Comorbidities (57/85 [67.1%]) were not associated with worsened outcomes. However, pre-existing pulmonary disease and immunosuppression were associated with severe PARDS (12/20 [60.0%] vs 19/65 [29.2%]; P = .017), extracorporeal membrane oxygenation use (5/20 [25.0%] vs 3/65 [4.6%]; P = .016) and reduced ventilator free days (VFD) (15 [0, 19] vs 21 [6, 23]; P = .039), compared with those without them.
A small percentage of children fulfilling the PALICC definition had quickly reversible hypoxemia with likely alternate pathophysiology to PARDS. Patients with pulmonary comorbidities and immunosuppression had a more severe course of PARDS compared with others.
本研究描述了符合儿科急性肺损伤共识会议 (PALICC) 定义的儿科急性呼吸窘迫综合征 (PARDS) 患者的疾病轨迹,并评估了合并症对结局的影响。
这是一项于 2017 年 11 月至 2019 年 10 月在单中心多学科儿科重症监护病房 (PICU) 进行的前瞻性研究,纳入了年龄<21 岁且需要机械通气<3 天的 PARDS 患者。对这些患者的临床病史进行了询问,并确定了不太可能诊断为 PARDS 的病例。分析了慢性合并症,特别是肺部疾病和免疫抑制对临床结局的影响。
在 1272 例 PICU 住院患者中,有 85 例(6.7%)符合 PARDS 标准并被纳入研究。中位年龄和氧合指数分别为 2.8(0.6,8.3)岁和 10.6(7.6,15.4)。总体死亡率为 85 例中的 12 例(14.1%)。尽管有 6/85(7.1%)例患者符合标准,但由支气管痉挛、黏液堵塞、液体超负荷和肺不张引起的低氧血症可迅速纠正,这些患者不太可能发生 PARDS。合并症(57/85 [67.1%])与不良结局无关。然而,既往肺部疾病和免疫抑制与严重 PARDS(12/20 [60.0%] vs 19/65 [29.2%];P = .017)、体外膜氧合(ECMO)使用(5/20 [25.0%] vs 3/65 [4.6%];P = .016)和减少机械通气无天数(VFD)(15 [0,19] vs 21 [6,23];P = .039)有关,与无这些疾病的患者相比。
符合 PALICC 定义的一小部分儿童存在迅速纠正的低氧血症,其可能具有与 PARDS 不同的病理生理学机制。与其他患者相比,有肺部合并症和免疫抑制的患者 PARDS 病程更严重。